Nephro Care India IPO 2024: Dates, Price, Lot Size

What the IPO is and why it matters

Nephro Care India Ltd opened its SME initial public offering (IPO) for subscription on June 28, 2024, and the issue closed on July 2, 2024. The IPO is a book building issue and is listed on the NSE SME platform. The company is a healthcare provider focused on kidney-related treatment and care, with its treatment centre based in Kolkata. The offer is entirely a fresh issue, meaning there is no offer for sale component mentioned for this IPO. The issue size is stated at ₹41.26 crore, and the face value is ₹10 per share. For retail investors, the large lot size and corresponding ticket size are a key feature of this offer. The IPO also comes at a time when market participants are tracking regulatory changes that can reshape retail participation in SME IPOs.

IPO price band, lot size, and minimum investment

The IPO price band is ₹85 to ₹90 per share, and the lot size is 1,600 shares. This structure makes the minimum application amount sensitive to the price selected within the band. At ₹90 per share, one lot works out to ₹1,44,000 for a retail application of 1,600 shares. Another stated minimum investment figure is ₹1,36,000, which corresponds to 1,600 shares at ₹85 per share. The article data also notes that a retail-individual investor can apply for up to 1 lot in this issue. For non-institutional investors (HNI), the minimum lot size investment is stated as 2 lots or 3,200 shares, amounting to ₹2,88,000 at the upper price.

Key dates: open, close, allotment, and listing

The issue opened on Friday, June 28, 2024 and closed on Tuesday, July 2, 2024. The basis of allotment date is July 3, 2024. Refund initiation and credit of shares to demat accounts are both dated July 4, 2024. The listing date is July 5, 2024 on NSE SME. These dates form the core timeline for applicants tracking ASBA blocks, allotment finalisation, and expected demat credit.

Issue size and structure: fresh issue only

Nephro Care India’s IPO is described as a ₹41.26 crore book build issue. The offer is stated to be entirely a fresh issue, with no offer for sale component. The equity shares are issued at a face value of ₹10. The data also mentions 4,584,000 equity shares as part of the fresh issuance. For investors, the fresh-issue-only nature typically means the funds raised are intended to go to the company for stated objectives, rather than to existing shareholders.

Anchor investors and investor category allocation

The company raised about ₹11.15 crore from anchor investors on June 27, 2024, as cited. The article data also provides category-wise share allocation figures: the retail (RII) portion accounts for 14.44 lakh equity shares, the HNI portion is allocated 6.19 lakh equity shares, the net QIBs are allocated 8.25 lakh equity shares, and anchor investors are allocated 12.38 lakh equity shares. In addition, the market maker is allocated 2.3 lakh equity shares, and employees are designated 2.25 lakh equity shares. The issue includes a reservation of up to 2,25,600 shares for employees offered at a discount of ₹0.00 to the issue price.

Company snapshot: business and location

Incorporated in 2014, Nephro Care India Limited is described as a comprehensive treatment centre located in Kolkata, offering renal insufficiency treatment along with clinical and lifestyle solutions. The company was established in 2014 by Dr. Pratim Sengupta in Kolkata, according to the cited RHP details. It is also described as a one-stop clinic with headquarters in Kolkata for kidney-related care. The company’s address is listed as Flat No.1JC-18 5th Flr Sec-III, Salt Lake, Bidhan Nagar, Kolkata-700098. Contact details provided include phone +91 80170 10197, email cs@nephrocareindia.com, and website www.nephrocareindia.com.

How the IPO proceeds are proposed to be used

The stated utilisation in the RHP is specific. Net proceeds of ₹26.17 crore are planned to be used to establish the “Vivacity Multi Speciality Hospital” in Madhyamgaram, Kolkata, West Bengal. The remaining funds are planned for general corporate purposes. Investors typically track such end-use disclosures to understand whether proceeds are directed toward capacity creation, new facilities, or balance-sheet strengthening.

Merchant banker, registrar, and market maker

The book running lead manager is Corporate Capitalventures Pvt Ltd. The registrar is Bigshare Services Pvt Ltd, with contact details listed as phone +91-22-62638200, email ipo@bigshareonline.com, and website www.bigshareonline.com. The market maker for the issue is Ss Corporate Securities. These intermediaries manage the IPO process, including book building, allotment coordination, and post-issue processes such as refunds and demat credit.

Grey market indication mentioned in the data

The article data cites an expected listing indication based on grey market premium: an expected listing price of ₹245 per share, described as 172.22% higher than the IPO price of ₹90. This is presented as a market indication rather than an official outcome, and such signals can change quickly based on subscription demand and broader market conditions. Investors generally treat grey market references as informal and not guaranteed.

Regulatory changes to SME IPOs highlighted

The data includes a note on regulatory changes to SME IPOs: the “Individual investor category will replace the Regular category for SME IPOs,” the minimum investment is stated as ₹2,00,000 and 2 lots, cut-off prices will no longer be applicable, bidding ends at 4:00 PM on the closing date, and bids cannot be canceled or edited after applying. This context matters because SME IPO participation is strongly affected by application ticket sizes and bidding rules. Investors tracking SME IPOs often compare current terms with upcoming regulatory requirements.

Key facts at a glance

Timeline for investors

Conclusion

Nephro Care India Ltd’s SME IPO is structured as a ₹41.26 crore fresh issue with a ₹85-₹90 price band and a 1,600-share lot size, keeping the retail ticket size between ₹1.36 lakh and ₹1.44 lakh. The post-issue schedule runs quickly from allotment on July 3 to listing on July 5, 2024. The company has also disclosed a specific end-use plan, including funding for setting up the Vivacity Multi Speciality Hospital in Madhyamgaram, Kolkata. Investors tracking SME issues will also watch how the highlighted regulatory changes affect application behaviour and participation rules going forward.